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Breast	   cancer	   is	   the	   second	   most	   common	   cancer	   worldwide	   and	   the	   most	   common	   cancer	  
reported	   in	   women.	   This	   malignant	   tumour	   is	   characterised	   by	   a	   number	   of	   specific	   features	  
including	   uncontrolled	   cell	   proliferation.	   It	   ranks	   fifth	   in	   the	   world	   as	   a	   cause	   of	   cancer	   death	  
overall	  in	  developed	  countries	  and	  is	  the	  second	  most	  frequent	  cause	  of	  cancer	  death	  in	  women.	  	  
Early	  diagnosis	   increases	  5-­‐year	  survival	  rates	  up	  to	  95%.	  Heparan	  sulfate	  proteoglycans	  (HSPGs)	  
are	  complex	  proteins	  composed	  of	  a	  core	  protein	  to	  which	  a	  number	  of	  highly	  sulfated	  side	  chains	  
attach,	   ubiquitous	   to	   the	   cell	   surface	   and	  within	   the	  extracellular	  matrix.	   	  HSPG	   side	   chains	   are	  
synthesised	   by	   a	   highly	   co-­‐ordinated	   process	   resulting	   in	   distinct	   sulfation	   patterns,	   which	  
determine	   specific	   interactions	   with	   cell-­‐signalling	   partners	   including	   growth	   factors,	   their	  
receptors,	   ligands	  and	  morphogens.	  The	  enzymes	  responsible	  for	  chain	  initiation,	  elongation	  and	  
sulfation	  are	  critical	  for	  creating	  HS	  chain	  variability	  conferring	  biological	  functionality.	  	  This	  study	  
investigated	   a	   single	   nucleotide	   polymorphism	   in	   SULF1,	   the	   enzyme	   responsible	   for	   the	   6-­‐O	  
desulfation	  of	  heparan	  sulfate	   side	  chains.	   	  We	   investigated	   this	  SNP	   in	  an	  Australian	  Caucasian	  
case-­‐control	   breast	   cancer	   population	   and	   found	   a	   significant	   association	   between	   SULF1	   and	  
breast	   cancer	   at	   both	   the	   allelic	   and	   genotypic	   level	   (allele,	   p=0.016;	   genotype,	   p=0.032).	   Our	  
results	  suggest	  the	  rs2623047	  SNP	  in	  SULF1	  may	  impact	  breast	  cancer	  susceptibility.	  Specifically,	  
the	  T	  allele	  of	  rs2623047	  in	  SULF1	  is	  associated	  with	  a	  increased	  risk	  of	  developing	  breast	  cancer	  in	  
our	  cohort.	  The	  identification	  of	  markers	  including	  SULF1	  may	  improve	  detection	  of	  this	  disease	  at	  
its	  earliest	  stages	  improving	  patient	  treatment	  and	  prognosis.	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Introduction	  
Breast	  cancer	  is	  the	  second	  most	  common	  cancer	  worldwide	  (1.4	  million	  cases,	  10.9%)	  and	  is	  the	  
most	   common	   form	   of	   cancer	   in	   women	   in	   all	   major	   regions	   of	   the	  world	   (ABS	   2011)	   with	   an	  
estimated	   1.67	   million	   new	   cancer	   cases	   diagnosed	   (25%	   of	   all	   cancers)	   in	   2012	   (Ferlay	   J,	  
Soerjomataram	  I	  et	  al.	  2013).	  It	  ranks	  fifth	  as	  cause	  of	  death	  (522,000,	  6.1%)	  in	  the	  world,	  and	  it	  is	  
the	  most	  frequent	  cause	  of	  cancer	  death	  in	  women	  (324,000	  deaths,	  14.3%	  of	  total)	  (Ferlay,	  Shin	  
et	  al.	  2010)	  in	  less	  developed	  regions	  and	  the	  second	  most	  common	  cause	  of	  cancer	  death	  in	  more	  
developed	   regions	   (198,000,	   15.4%).	  Non-­‐modifiable	   risk	   factors	   increase	   the	   risk	   of	   developing	  
breast	  cancer	   including:	  gender,	  age	   (50%	  of	  women	  diagnosed	  are	  between	   the	  ages	  of	  50-­‐69)	  
(2006);	  breast	  cellular	  changes,	  including	  increased	  volume;	  personal	  history	  (previous	  diagnosis),	  
family	  history	  of	  breast	  cancer	  (first-­‐degree	  relative)	  and	  genetic	  factors	  (2010).	  	  	  	  
Breast	   volume	   (i.e	   80%)	   is	   mainly	   attributed	   to	   the	   stroma	   comprised	   of	   collagen,	   fibroblasts,	  
endothelial	   cells,	   adipocytes	   and	   a	   molecular	   network	   of	   proteoglycans.	   Stromal	   cells	   are	  
embedded	  within	  the	  extracellular	  matrix	  (ECM)	  and	  provide	  a	  scaffold	  for	  cancer	  cells	  as	  well	  as	  
producing	   ECM	   constituents	   for	   use	   by	   these	   cells.	   The	   two	   current	   models	   for	   tumour	  
heterogeneity,	   the	   cancer	   stem	   cell	   hypothesis	   and	   the	   clonal	   evolution	   model,	   allow	   for	   a	  
contribution	  from	  the	  acquisition	  of	  genetic	  events,	  epigenetic	  and	  microenvironmental	  changes	  
in	   the	   metastasis	   and	   progression	   of	   cancer	   (Haupt	   and	   Griffiths	   2009).	   	   Increasing	   evidence	  
suggests	   there	   is	   extensive	   interaction	   between	   the	   tumour	   cells	   and	   the	   surrounding	   stromal	  
compartment	   with	   both	   cells	   contributing	   to	   factors	   necessary	   for	   tumour	   survival	   (Haupt	   and	  
Griffiths	  2009).	  Key	  constituents	  of	  this	  microenvironment,	  proteoglycans	  (PGs)	  are	  composed	  of	  a	  
core	  protein	  to	  which	  a	  number	  of	  glycosaminoglycan	  (GAGs)	  side	  chains	  are	  attached	  (Bernfield,	  
Gotte	   et	   al.	   1999)	   and	   include	   the	   heparan	   sulfate	   proteoglycans	   (HSPGs),	   a	   family	   of	   PGs	  
predominantly	  decorated	  with	  heparan	  sulfate	  (HS)	  chains.	  	  HSPGs	  are	  ubiquitous	  to	  the	  cell	  niche	  
and	   interact	   with	   a	   large	   number	   of	   ligands	   including	   growth	   factors,	   their	   receptors	   and	   ECM	  
structural	   components	   (Haupt	   and	   Griffiths	   2009).	   Localised	   to	   both	   the	   cell	   surface	   and	   the	  
extracellular	  matrix	  (ECM),	  HSPGs	  are	  composed	  of	  a	  core	  protein	  to	  which	  a	  side	  chain	  of	  varying	  
length	  and	  sulfation	  pattern	  is	  attached	  (Blackhall,	  Merry	  et	  al.	  2001,	  Fernandez-­‐Vega,	  Garcia	  et	  al.	  
2013).	   The	   heparan	   sulfate	   (HS)	   chains	   are	   synthesised	   by	   the	   addition	   of	   repeating	   units	   of	  
unbranched	  disaccharides	  composed	  of	  alternate	  residues	  of	  N-­‐acetylglucosamine	  and	  glucuronic	  
acid	   (Gallagher	   2001,	   Sugahara	   and	   Kitagawa	   2002).	   The	   highly	   sulfated	   regions	   of	   HS	   are	  
5 
responsible	  for	  most	  of	  the	  biological	  activity	  due	  to	  their	  charged	  interactions	  with	  basic	  amino	  
acid	  clusters	   in	  proteins	  with	   the	  pattern	  of	   sulfation	   the	   significant	   contributor	   to	   their	  diverse	  
biological	  activity	  (Gallagher	  2001).	  	  
HSPGs	  have	  important	  roles	  in	  key	  biological	  functions	  in	  tissues,	  in	  both	  normal	  and	  pathological	  
conditions,	  dependent	  on	   chain	   structure.	  HSPGs	  have	  been	  demonstrated	   to	  play	  a	   role	   in	   cell	  
adhesion	   and	   migration,	   organisation	   of	   the	   extra-­‐cellular	   matrix,	   differentiation	   and	  
morphogenesis,	  along	  with	  cancer	  metastasis	  and	  the	  regulation	  of	  proliferation	  (Gallagher	  2001).	  
In	   breast	   tissue,	   the	   intralobular	   stroma	   rich	   in	   PGs	   mediates	   hormonally	   induced	   changes	   in	  
breast	  volume	  (Wiseman	  and	  Werb	  2002).	  However,	  these	  functions	  can	  be	  altered	  and	  regulated	  
in	  several	  pathophysiological	  processes,	  such	  as	  cancer	  (Blackhall,	  Merry	  et	  al.	  2001),	  with	  genes	  
involved	  in	  the	  biosynthesis	  of	  these	  elements	  up-­‐	  or	  down-­‐	  regulated.	  
Many	  studies	  have	  associated	  HSPG	  core	  proteins	  and	  their	  modification	  enzymes	  with	  cancer	  and	  
cancer-­‐like	   diseases,	   most	   likely	   due	   to	   alterations	   in	   HSPG	   function	   and	   regulation	   of	   cell	  
behaviour	   (Blackhall,	  Merry	   et	   al.	   2001,	  Gallagher	   2001).	   Core	   proteins	   carrying	  HS	   chains	   have	  
previously	  been	   implicated	   in	  breast	   cancer	  development	  with	   increased	  expression	  of	   the	   core	  
protein	   syndecan-­‐1	   (SDC1)	   associated	  with	  more	   severe	   forms	   of	   the	   disease	   (Lendorf,	  Manon-­‐
Jensen	   et	   al.	   2011).	   More	   recently,	   the	   gene	   expression	   profile	   of	   HSPG	   chain	   initiation	   and	  
modification	  enzymes	  as	  well	  as	  HSPG	  core	  proteins	  was	  examined	  following	  heparin	  treatment	  in	  
vitro.	  Changes	  in	  gene	  expression	  was	  observed	  for	  O-­‐sulfation	  enzymes	  (2-­‐O	  and	  6-­‐O)	  as	  well	  as	  
core	   syndecan	   proteins	   (SDC2	   and	   SDC4)	   along	   with	   altered	   proliferation,	   viability	   and	  
tumourigeneity	   of	   these	   cells	   (Okolicsanyi,	   van	   Wijnen	   et	   al.	   2013).	   Specifically,	   decreased	  
expression	  of	  HS6ST1,	  an	  enzyme	  responsible	  for	  the	  addition	  of	  6-­‐O	  sulfation	  was	  observed	  in	  the	  
lowly	   invasive,	   poorly	   metastatic	   MCF-­‐7	   cells	   following	   heparin	   treatment,	   while	   the	   same	  
treatment	  produced	  an	  increase	  in	  expression	  in	  the	  highly	   invasive,	  highly	  metastatic	  MDA-­‐MB-­‐
231	  cells	  (Okolicsanyi,	  van	  Wijnen	  et	  al.	  2013).	  	  
The	   heparan	   sulfatases	   are	   a	   family	   of	   HSPG	   enzymes	   that	   modulate	   HSPG/growth	   factor	  
interactions	  and	  subsequent	  downstream	  signalling	  through	  modification	  of	  the	  HS	  side	  chain	  and	  
includes	  HS	   6-­‐O-­‐endosulfatase	   1	   (SULF1)	   (Morimoto-­‐Tomita,	  Uchimura	   et	   al.	   2002,	   Ai,	   Do	   et	   al.	  
2003,	   Isidor,	   Pichon	   et	   al.	   2010).	   SULF1	   removes	   the	   6-­‐O-­‐sulfate	   group	   from	   heparan	   sulfate	  
chains,	   modulating	   HSPG	   function	   by	   altering	   binding	   through	   catalysing	   HSPG	   6-­‐O	   desulfation	  
(Morimoto-­‐Tomita,	   Uchimura	   et	   al.	   2002,	   Ai,	   Do	   et	   al.	   2003).	   SULF1	   and	   cancer	   risk	   have	   been	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correlated	   in	   several	   gene	   expression	   studies	   (Han,	  Huang	   et	   al.	   2011)	  with	   down	   regulation	  of	  
SULF1	   described	   in	  malignant	   breast	   cancer	   cells.	   Similarly,	   in	   vitro	   overexpression	   of	  SULF-­‐1	   in	  
hepatocarcinoma	   (HCC)	   cells	   decreased	   sulfation	   of	   cell-­‐surface	   HSPGs	   and	   reduced	   growth	  
signalling	  (Lai,	  Chien	  et	  al.	  2003).	  In	  addition,	  increased	  SULF1	  expression	  has	  been	  associated	  with	  
increased	   overall	   survival	   from	   breast	   cancer,	   and	   poorly	   invasive	   tumours	   such	   as	   lobular	  
carcinomas	  (Khurana,	  Beleford	  et	  al.	  2013).	  	  
The	   development	   of	   targeted	   therapeutics	   is	   dependant	   on	   the	   identification	   of	   genetic	   and	  
microenvironmental	   changes	   involved	   in	   the	   initiation,	  progression	  and	  malignant	   conversion	  of	  
cancers	  (Haupt	  and	  Griffiths	  2009).	  The	  ability	  of	  cancers	  to	  exploit	  HSPG	  function	  within	  their	  cells	  
makes	   SNPs	   within	   HSPG	   genes	   potential	   markers	   of	   cancer	   disease	   susceptibility.	   Here,	   we	  
examined	   the	   SULF1	   SNP	   rs2623047	   in	   Australian	   Caucasian	   breast	   cancer	   cohorts	   using	   two	  
independent	   breast	   cancer	   case/control	   populations.	   Initial	   genotyping	   was	   conducted	   on	   the	  
Genomics	   Research	   Centre	   Breast	   Cancer	   population	   with	   results	   replicated	   in	   the	   Griffith	  
University-­‐Cancer	   Council	   Queensland	   Breast	   Cancer	   Biobank	   population.	   Genotyping	   was	  
performed	  using	  PCR-­‐RFLP	   analysis	   to	   examine	   the	  potential	   of	   this	   SNP	  as	   a	  marker	   for	   breast	  
cancer	  susceptibility.	  	  
	  
Materials	  and	  Methods	  
Populations	  
All	   individuals	  comprising	  the	  two	  populations	  are	  of	  Caucasian	  (Northern	  European)	  origin.	   	  The	  
initial	   Genomics	   Research	   Centre	   breast	   cancer	   (GRC-­‐BC)	   population	   consisted	   of	   243	   breast	  
cancer	  patient	   samples	  and	  201	  age	  and	   sex	  matched	  control	   samples.	   	  A	   subset	  of	   the	  Griffith	  
University-­‐Cancer	  Council	  Queensland	  Breast	  Cancer	  Biobank	  (GU-­‐CCQ	  BB)	  population	  was	  used	  as	  
a	  replication	  population	  and	  consisted	  of	  443	  case	  samples	  and	  91	  age	  and	  sex	  matched	  controls	  
(Youl,	  Baade	  et	  al.	  2011).	  	  
In	  collaboration	  with	  the	  Cancer	  Council	  Queensland,	  the	  Genomics	  Research	  Centre	  has	  collected	  
samples	  for	  the	  GU-­‐CCQ	  BB	  population	  as	  part	  of	  a	  5-­‐year	  population-­‐based	  longitudinal	  study	  of	  
women	  newly	  diagnosed	  with	  breast	  cancer.	  	  Recruitment	  commenced	  in	  January	  2011	  with	  920	  
women	  aged	  33	  to	  80	  years	  (average	  age	  60.2	  years)	  available	  for	  this	  study.	  Study	  participants	  are	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residents	   of	   Queensland	   with	   a	   histologically	   confirmed	   diagnosis	   of	   invasive	   breast	   cancer.	  
Clinical	   and	   demographic	   information	   was	   obtained	   from	   the	   Queensland	   Cancer	   Registry	   and	  
diagnostic	   and	   treatment	   information	   was	   obtained	   through	   telephone	   interviews	   with	  
participants	  and	  medical	  record	  extraction.	  The	  matching	  control	  population	  includes	  women	  with	  
no	  personal	  or	  familial	  history	  of	  cancer	  aged	  32	  to	  88	  years,	  with	  an	  average	  age	  of	  60.2	  years.	  
These	  women	  were	  recruited	  through	  the	  Genomics	  Research	  Centre	  from	  January	  2000.	  
Preparation	  of	  DNA	  samples	  from	  Blood	  
DNA	  was	  extracted	  from	  blood	  samples	  using	  a	  modified	  salting	  out	  method	  (Nasiri,	  Forouzandeh	  
et	  al.	  2005,	  Chacon-­‐Cortes,	  Haupt	  et	  al.	  2012).	  Quality	  and	  quantity	  of	  isolated	  DNA	  was	  measured	  
by	   spectrophotometry	  using	  a	  Nanodrop	   (Thermo	  Scientific,	  Australia).	   If	   required	  DNA	  samples	  
were	  further	  purified	  by	  ethanol	  precipitation	  as	  described	  (Buckingham	  2007).	  
SNP	  selection	  and	  primer	  design	  
The	  SULF1	  SNP	  rs2623047	  was	  identified	  following	  consideration	  of	  a	  number	  of	  HSPG	  SNPs	  where	  
a	  minor	  allele	  frequency	  (MAF)	  greater	  than	  0.05	  was	  considered	  during	  the	  selection	  and	  design	  
process.	  	  This	  SNP	  is	  a	  5’	  near	  gene	  polymorphism	  significantly	  associated	  with	  early	  onset	  age	  and	  
longer	  progression	  free	  survival	   in	  ovarian	  cancers	  (Han	  et	  al.,	  2011).	  Chromosomal	   location	  and	  
MAF	  for	  this	  SNP	  can	  be	  found	  in	  Table	  1.	  Primers	  were	  designed	  using	  NCBI	  Primer	  Blast	  with	  the	  
sequences	  F	  (5’-­‐GGGATGCACAGAAACCCTAA-­‐3’)	  and	  R	  (5’-­‐TGTGGCAAACAGTGAAGAGC-­‐3’)	  used	  to	  
amplify	  a	  291bp	  fragment.	  
PCR	  Amplification	  
PCR	  amplification	  of	  the	  region	  surrounding	  the	  SULF1	  SNP	  (rs2623047)	  was	  conducted	  under	  the	  
following	  conditions:	  40ng	  of	  DNA	  was	  amplified	  with	  100nM	  each	  forward	  and	  reverse	  primers	  
(IDT,	   USA),	   200nM	   dNTPs	   (NEB,	   Australia),	   1.75mM	  MgCl2,	   0.5U	   GoTaq®	   Flexi	   DNA	   polymerase	  
(Promega,	  Australia),	  1x	  PCR	  buffer	  in	  a	  15	  μL	  reaction.	  An	  initial	  3	  min	  denaturation	  step	  at	  95oC	  
was	  followed	  by	  35	  cycles	  of	  denaturation	  at	  95oC	  for	  45s,	  annealing	  at	  58oC	  for	  45s	  and	  extension	  
at	  72oC	   for	  45s.	  A	   final	  extension	  step	  of	  7	  min	  at	  72oC	  completed	  the	  cycling.	  These	  conditions	  
produced	  a	  single	  291bp	  fragment.	  Following	  amplification,	  the	  PCR	  product	  was	  held	  at	  4oC	  until	  
genotyping	  analysis.	  	  
Restriction	  Fragment	  Length	  Polymorphism	  (RFLP)	  analysis	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Genotyping	   was	   conducted	   using	   restriction	   fragment	   length	   polymorphism	   (RFLP)	   analysis.	  
Following	  amplification,	  approximately	  1μg	  (7μL)	  PCR	  product	  was	  digested	  with	  1U	  PspGI	  enzyme	  
for	   4hr	   at	   75oC	   with	   1x	   reaction	   buffer	   in	   a	   15μL	   reaction.	   The	   PspGI	   enzyme	   recognises	   the	  
sequence	  CCWGG	  and	  cuts	  the	  amplicon	  when	  the	  wild	  type	  (C)	  allele	  is	  present	  creating	  bands	  of	  
212bp	  and	  78bp.	  The	  enzyme	  is	  unable	  to	  cut	  the	  fragment	  when	  the	  mutant	  (T)	  allele	  is	  present.	  	  
Agarose	  Gel	  Electrophoresis	  
To	  confirm	  amplification	  of	  the	  fragment	  of	  interest,	  the	  PCR	  product	  was	  run	  on	  3%	  agarose	  gels	  
in	  1x	  Tris-­‐acetate-­‐EDTA	  (TAE)	  buffer	  at	  90V	  for	  45	  min.	  For	  genotyping	  analysis	  following	  RFLP,	  the	  
digested	   PCR	   product	   was	   run	   on	   a	   4%	   agarose	   gel	   in	   1x	   TAE	   at	   70V	   for	   60min	   for	   increased	  
resolution.	  	  A	  100bp	  DNA	  ladder	  was	  included	  for	  sizing	  purposes	  with	  DNA	  fragments	  visualised	  
following	  the	  addition	  of	  ethidium	  bromide	  and	  excitation	  under	  UV	  light.	  
Statistical	  tests	  
Allele	  frequencies	  in	  case	  and	  control	  populations	  were	  determined.	  Hardy-­‐Weinberg	  Equilibrium	  
(HWE)	  (Kalmes	  R	  February,	  2001)	  was	  used	  to	  test	  for	  deviation	  between	  observed	  and	  expected	  
frequencies.	  A	  Chi-­‐squared	  analysis	  (Fisher	  and	  Yates	  1963)	  was	  conducted	  to	  test	  for	  significant	  
differences	   between	   case	   and	   control	   populations	   and	   to	   determine	   if	   the	   alleles	   or	   genotypes	  
were	  significantly	  associated	  with	  breast	  cancer	  (α=0.05).	  The	  odds	  ratio	  at	  a	  confidence	  interval	  
of	  95%	  was	  calculated	  to	  indicate	  disease	  risk.	  	  
	  
Results	  
The	   SULF1	   SNP	   rs2623047	   was	   initially	   analysed	   the	   GRC	   breast	   cancer	   cohort.	   Both	   case	   and	  
control	  populations	  were	  determined	  to	  be	  in	  HWE	  (case,	  p=0.17;	  control,	  p=0.38).	  Our	  observed	  
frequencies	   in	   the	   control	   population	   closely	  matched	   those	   found	  on	  HapMap	   for	   a	   Caucasian	  
population	  with	  a	  calculated	  Odds	  Ratio	  (OR)	  of	  0.72.	  When	  Chi-­‐squared	  analysis	  was	  conducted	  
to	   determine	   association,	   a	   significant	   difference	   between	   the	   case	   and	   control	   populations	   at	  
both	  the	  genotypic	  and	  allelic	  level	  was	  observed	  (summarised	  in	  Table	  2).	  	  
We	   then	   examined	   the	   SNP	   in	   an	   independent	   replication	   population,	   the	   GU-­‐CCQ	   BB	   cohort.	  	  
Once	  again,	  both	  case	  and	  control	  samples	  were	  determined	  to	  be	  in	  HWE	  (case,	  p=0.53;	  control,	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p=0.46).	  Chi-­‐squared	  analysis	  determined	  borderline	  significance	  at	  the	  allelic	  level	  (p=0.057)	  and	  
no	  significant	  difference	   in	  genotype	   frequencies	   (p=0.15)	  with	  an	  OR	  of	  0.72.	  These	   results	  are	  
summarised	  in	  Table	  3.	  	  
Due	  to	  the	  small	  number	  of	  control	  samples	  in	  the	  GU-­‐CCQ	  BB	  cohort,	  we	  combined	  the	  data	  from	  
the	  two	  independent	  populations	  and	  analysed	  them	  together,	  increasing	  the	  power	  of	  the	  study.	  
When	   analysed	   together,	   the	   combined	   population	   once	   again	   reached	   significance.	   	   Both	  
combined	  cases	  and	  combined	  controls	  were	  demonstrated	  to	  be	  in	  HWE	  (case,	  p=0.77;	  control,	  
p=0.27)	   with	   chi-­‐square	   analysis	   determining	   significant	   differences	   between	   case	   and	   control	  
samples	  at	  both	   the	  allelic	  and	  genotypic	   level	   including	  an	  odds	   ration	  of	  0.77.	   	  The	  calculated	  
odds	  ratios	  obtained	  suggest	  the	  presence	  of	  the	  T	  allele	  within	  the	  rs2623047	  SNP	  is	  associated	  




In	  this	  study	  we	  examined	  the	  potential	  association	  of	  the	  SULF1	  SNP	  rs2623047	  in	  breast	  cancer	  
susceptibility.	   Our	   results	   demonstrated	   a	   significant	   difference	   in	   allele	   (p=0.03)	   and	   genotype	  
(p=0.03)	  frequencies	  in	  an	  Australian	  Caucasian	  population.	  	  Results	  of	  a	  replication	  study	  found	  a	  
similar	  trend,	  although	  this	  study	  failed	  to	  reach	  levels	  for	  significance.	  There	  was	  no	  association	  at	  
the	   allelic	   level,	   however	   genotype	   frequencies	   showed	   borderline	   significance	   (p=0.057).	  
However,	  when	  the	  two	  populations	  were	  combined	  to	   increase	  the	  power	  of	   the	  population,	  a	  
significant	   difference	   in	   allele	   and	   genotype	   frequencies	   was	   found	   (allele,	   p=0.016;	   genotype,	  
p=0.032).	  The	  lack	  of	  significance	  in	  the	  replication	  population	  could	  be	  due	  to	  the	  low	  number	  of	  
controls	   (n=80).	   However	   when	   data	   from	   the	   two	   populations	   was	   combined	   for	   analysis,	  
association	  of	  this	  SNP	  and	  breast	  cancer	  susceptibility	  was	  identified.	  	  
Biosynthesis	   of	   HSPGs	   is	   a	   complex	   process	   with	   mutations	   and	   alterations	   to	   expression	   of	   a	  
number	   of	   genes	   at	   various	   stages	   of	   this	   complex	   process	   previously	   associated	  with	   disease.	  
SULF1	  encodes	  heparan	  sulfate	  6-­‐O-­‐endosulfatase	  1,	  responsible	  for	  6-­‐O	  desulfation	  of	  HS	  chains	  
(Isidor,	  Pichon	  et	  al.	  2010).	  A	  number	  of	  genetic	  modifications	  have	  been	  reported	   in	  the	  SULF1	  
gene	  with	   SNPs	  within	   this	   gene	   associated	  with	   ovarian	   cancer,	   particularly	  with	   age	   of	   onset,	  
suggesting	  its	  variations	  may	  have	  roles	  in	  prognosis	  and	  onset	  of	  the	  disease	  (Han,	  Huang	  et	  al.	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2011).	   SULF1	   has	   also	   been	   shown	   to	   inhibit	   tumour	   growth	   in	   hepatocellular	   carcinoma	   (HCC)	  
through	  desulfation	  of	  cell	  surface	  of	  HSPGs	  resulting	  in	  the	  downregultion	  of	  HCC	  cell	  growth	  (Lai,	  
Yu	  et	  al.	  2006).	  In	  addition,	  SULF1	  overexpression	  in	  gastric	  cancer	  has	  been	  suggested	  to	  correlate	  
with	  the	  oncogene	  MYC	  amplification	  in	  HCCs,	  as	  both	  are	  located	  in	  the	  chromosomal	  region	  8q,	  
frequently	  amplified	  in	  gastric	  cancers	  (Junnila,	  Kokkola	  et	  al.	  2010).	  
Members	   of	   the	   two	  major	   HSPG	   core	   protein	   families,	   the	   glypicans	   (attached	   through	   a	   GPI	  
anchor	   to	   the	   cell	   membrane)	   and	   the	   syndecans	   (transmembrane	   proteins	   found	   in	   the	   cell	  
surface	  and	   the	  extracellular	  matrix),	  have	  also	  been	  associated	  with	  disease.	  Glypican-­‐3	   (GPC3)	  
acts	   as	   a	   cell	   proliferation	   inhibitor	   and	   apoptosis	   inducer	   in	   several	   tumour	   cell	   types,	  with	   its	  
gene	   expression	   down-­‐regulated	   in	   various	   types	   of	   tumours,	   including	   mesotheliomas	   and	  
ovarian	   cancer	   as	  well	   as	   Simpson-­‐Golabi-­‐Behmel	   syndrome	   (Gonzalez,	   Kaya	   et	   al.	   1998,	   Cano-­‐
Gauci,	  Song	  et	  al.	  1999,	  Filmus	  2001).	  Up-­‐regulation	  of	  GPC3	  has	  also	  been	  associated	  with	  cancer	  
with	  enhanced	  expression	  observed	  in	  thyroid	  cancer,	  indicating	  a	  tumour	  suppressive	  role,	  while	  
silencing	  GPC3	   in	   breast	   cancer	   demonstrated	   a	   negative	   regulatory	   role	   on	   cell	   growth	   (Xiang,	  
Ladeda	   et	   al.	   2001,	   Yamanaka,	   Ito	   et	   al.	   2007).	   These	   observed	   roles	   of	   GPC3	   appears	   to	   be	  
through	  its	  interactions	  with	  the	  Wnt	  signalling	  where	  it	  is	  able	  to	  inhibit	  both	  the	  canonical	  and	  
non-­‐canonical	  pathways	  (Schambony,	  Kunz	  et	  al.	  2004,	  Stigliano,	  Puricelli	  et	  al.	  2009).	  This	  has	  also	  
been	  demonstrated	  in	  vitro,	  where	  HSPG	  mediated	  human	  breast	  cancer	  cell	  line	  proliferation	  and	  
migration	  were	   shown	   to	   be	  mediated	   through	   interactions	  with	   specific	  members	   of	   the	  Wnt	  
pathway	   (Okolicsanyi,	   van	  Wijnen	  et	   al.	   2013),	   interactions	   that	  may	  be	  modified	   as	   a	   result	   of	  
changes	  to	  HS	  chain	  sulfation.	  
SDC1	  encodes	  the	  HSPG	  syndecan	  1	  (Zhang,	  McKown	  et	  al.	  2011),	  the	  most	  studied	  member	  of	  the	  
syndecan	   family	   of	   HSPGs	   (Gallagher	   2001)	   thought	   to	   have	   an	   important	   role	   in	   cancer	  
progression	  (Zhang,	  McKown	  et	  al.	  2011).	   	  Examination	  of	  dense	  breast	  tissue	  has	  demonstrated	  
higher	   expression	   of	   SDC1,	   suggesting	   overexpression	   is	   related	   to	   breast	   cancer	   with	   tissue	  
density	   a	   risk	   factor	   in	   breast	   cancer	   development	   (Lundstrom,	   Sahlin	   et	   al.	   2006).	   In	   addition,	  
increased	  SDC1	  expression	  has	  been	  associated	  with	  poorer	  prognosis	  for	  breast	  cancer	  patients	  
suggesting	   a	   role	   for	   this	   HSPG	   in	   more	   malignant	   and	   higher-­‐grade	   breast	   cancer	   tumours	  
(Lendorf,	  Manon-­‐Jensen	  et	  al.	  2011).	  Interestingly,	  SDC1	  mediated	  endocytosis	  has	  been	  shown	  to	  
be	  dependent	  on	  the	  presence	  of	  N-­‐	  and	  6-­‐O	  sulfation	  of	  SDC1	  HS	  chains	  (Makkonen,	  Turkki	  et	  al.	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2013).	  In	  addition,	  this	  was	  shown	  to	  be	  specific	  only	  to	  the	  SDC1	  core	  HSPG	  protein	  (Makkonen,	  
Turkki	  et	  al.	  2013).	  
Importantly,	  both	   these	  HSPG	  core	  protein	   families,	   the	   syndecans	  and	  glypicans,	  are	   reliant	  on	  
the	  fine	  structure	  of	   their	  HS	  chains	   for	  their	  molecular	   interactions	  and	  biological	   functions.	   	   In	  
Wnt-­‐signalling,	  glypicans	  stabilise	  the	  interaction	  of	  Wnt	  with	  its	  receptor	  Frizzled	  (Filmus,	  Capurro	  
et	  al.	  2008).	  The	  syndecans	  often	  act	  through	  interactions	  with	  the	  fibroblast	  growth	  factor	  (FGF)	  
family	  of	  growth	  factors,	  which	  require	  specific	  sulfation	  sites	  on	  HS	  chains	  to	  enable	  binding	  to	  
their	  signalling	  partners	  (Guimond,	  Maccarana	  et	  al.	  1993).	  Important	  roles	  for	  6-­‐O	  sulfation,	  and	  
therefore	   SULF1	   have	   also	   been	   identified	   in	   FGF	   signalling.	   For	   example,	   FGF2-­‐FGFR	   complex	  
binding	  requires	  2-­‐O	  sulfation,	  while	  interactions	  with	  PGDF	  require	  6-­‐O	  sulfation	  (Lindahl,	  Kusche-­‐
Gullberg	  et	  al.	  1998).	   Interactions	  of	  FGF1-­‐FGFR2	  require	  6-­‐O	  sulfation	  and	  FGF2-­‐FGFR1	  requires	  
both	   6-­‐O	   and	   2-­‐O	   sulfation	   (Pellegrini,	   Burke	   et	   al.	   2000).	   The	   ability	   of	   FGF-­‐2	   to	   bind	   its	   ‘high	  
affinity’	  receptor	  (FGFR-­‐1)	  to	  stimulate	  growth	  is	  greatly	  decreased	  in	  the	  absence	  of	  appropriately	  
sulfated	   HSPGs	   (Rapraeger,	   Krufka	   et	   al.	   1991,	   Ornitz,	   Yayon	   et	   al.	   1992).	   QSulf1,	   the	   avian	  
homologue	  of	  mammalian	  SULF1,	  has	  been	  shown	  to	  promote	  Wnt	  signalling	  by	  modulating	  the	  
binding	  affinity	  of	  Wnts	  to	  HS	  chains.	  This	  promotes	  HS-­‐mediated	   initiation	  of	  signalling	  through	  
presentation	  of	  Wnt	  to	  its	  receptor,	  Frizzled	  (Ai,	  Do	  et	  al.	  2003).	  	  SULF1	  was	  also	  shown	  to	  inhibit	  
FGF	  signalling	  activity	  in	  both	  Xenopus	  and	  chicken	  embryos	  (Wang,	  Ai	  et	  al.	  2004).	  These	  studies	  
suggest	  a	  role	  for	  SULF1	  as	  a	  positive	  regulator	  of	  Wnt	  signalling	  and	  a	  negative	  regulator	  of	  FGF	  
signalling	  (Lin	  2004).	  	  
These	  examples	   also	  demonstrate	   the	   importance	  of	   the	   sulfation	  pattern	  of	  HS	   side	   chains	   for	  
their	  biological	  function.	  	  As	  such,	  the	  enzymes	  regulating	  both	  sulfation	  and	  desulfation	  of	  HSPG	  
side	   chains	   have	   a	   critical	   impact	   on	   the	   regulation	   of	   a	   number	   of	   cellular	   processes.	   The	  
mutation	  of	   the	  allele	  C	   to	  T	   in	  SULF1	   in	   the	   rs2623047	  SNP	   results	   in	   changed	  heparan	   sulfate	  
endosulfatase	   function	   and	   the	   removal	   of	   6-­‐O-­‐sulfate	   groups	   from	   heparan	   sulfate	   chains.	   As	  
such,	  modifications	  to	  the	  HS	  chain	  through	  the	  action	  of	  enzymes	  such	  as	  SULF1	  influence	  cell-­‐cell	  
and	   cell-­‐matrix	   interactions	   in	   both	   healthy	   and	   disease	   tissues.	   Further	   examination	   of	   the	  
protein	   levels	  of	  SULF1	   in	   tumour	   tissue	  would	  add	   to	  our	  understanding	  of	   the	   involvement	  of	  
this	  protein	  in	  breast	  cancer	  progression.	  In	  addition,	  studies	  examining	  the	  effect	  of	  modification	  
of	   HS	   sulfation	   through	   the	   addition	   of	   sulfation	   inhibitors	   such	   as	   sodium	   chlorate	   to	   in	   vitro	  
models	  may	  provide	   a	   better	   insight	   into	   the	   role	   of	   SULF1	   and	  other	  HSPGs	   in	   breast	   cancers,	  
12 
including	  their	   interaction	  with	  specific	  growth	  factors	  such	  as	  the	  FGFs	   in	  terms	  of	  downstream	  
signalling	  affecting	  cell	  proliferation,	  differentiation	  and	  migration	  of	  tumour	  cells.	  
Conclusion	  
Breast	  cancer	   is	  an	  often-­‐fatal	  disease	  affecting	  a	  significant	  number	  of	  women	  worldwide.	  With	  
genetic	  susceptibility	  one	  of	  the	  numerous	  factors	  contributing	  to	  the	  development	  of	  this	  disease	  
we	  examined	  the	  SNP	  (rs2623047)	  in	  SULF1	  as	  a	  potential	  marker	  of	  genetic	  susceptibility	  in	  this	  
disease.	  In	  the	  first	  study	  of	  its	  kind	  investigating	  SNPs	  in	  the	  gene	  encoding	  the	  HSPG	  modification	  
enzyme,	   our	   results	   demonstrate	   that	   the	   T	   allele	   of	   rs2623047	   in	   SULF1	   is	   associated	  with	   an	  
increased	  risk	  of	  developing	  breast	  cancer.	  Identification	  of	  markers	  including	  those	  within	  central	  
roles	  in	  the	  stroma	  and	  matrix	  surrounding	  breast	  tumour	  cells	  may	  enable	  improved	  detection	  of	  
this	  disease	  at	  an	  earlier	  stage	  to	  improve	  treatment	  regimes	  and	  patient	  prognosis.	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Table 2: Genotypes for SULF-1 (rs2623047) obtained from the GRC Breast cancer 
population	  
Allele Genotype  
 T (%) C (%) p-value TT (%) CT (%) CC (%) p-value 
Control 208 (59.4) 142 (42.6) 0.028 59 (31.1) 90 (56.6) 26 (16.4) 0.027 
Case 270 (63.2) 132 (40.6)  95 (46.6) 80 (39.2) 26 (12.7)  




Table 3: Genotypes for SULF-1 (rs2623047) obtained from the GHI Biobank cohort	  
Allele Genotype 
 T (%) C (%) p-value TT (%) CT (%) CC (%) 
p-
value 
Control 87 (54.4) 73 (45.6) 0.057 22 (27.5) 43 (53.8) 15 (18.8) 0.15 
Case 503 (62.4) 303 (37.6)  154 (38.2) 
195 
(48.4) 
54 (62.4)  
HapMap 58.4 41.6  32.7 51.3 15.9  
	  
 
Table 4: Genotypes for SULF-1 (rs2623047) obtained from the combined populations	  
Allele Genotype 
 T (%) C (%) p-value TT (%) CT (%) CC (%) 
p-
value 
Control 295 (57.8)  215 (42.2) 0.016 81 (31.8) 
133 
(52.2) 
41 (16) 0.032 
Case 773 (64.0) 435 (36.0)  249 (41.2) 
275 
(45.5) 
80 (13.3)  
HapMap 58.4 41.6  32.7 51.3 15.9  
 
